Neutralizing Antibody Responses in Macaques Induced by Human Immunodeficiency Virus Type 1 Monovalent or Trivalent Envelope Glycoproteins

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Quinnan, Gerald V ^a   Zhang, Pengfei ^a   Dong, Ming ^a   Chen, Hong ^a   Feng, Yan Ru ^a   Lewis, Mark ^b   Broder, Christopher C ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BIOQUAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 140; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 140; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPRECIPITATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; RABBIT; RHESUS MONKEY; VIRUS MUTATION;

EID: 84875343247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059803     Document Type: Article

References (67)

1. Beirnaert E, De Zutter S, Janssens W, van der Groen G, (2001) Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells. Virology 281: 305-314.
2. Quinnan GV Jr, Zhang PF, Fu DW, Dong M, Alter HJ, (1999) Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retroviruses 15: 561-570.
3. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, et al. (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81: 6548-6562.
4. Donners H, Willems B, Beirnaert E, Colebunders R, Davis D, et al. (2002) Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1. Aids 16: 501-503.
5. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, et al. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6: e1001028.
6. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84: 1631-1636.
7. Nandi A, Lavine CL, Wang P, Lipchina I, Goepfert PA, et al. (2010) Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396: 339-348.
8. Sather DN, Stamatatos L, (2010) Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 28Suppl 2: B8-12.
9. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
10. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, et al. (2002) Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 99: 6913-6918.
11. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
12. Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, et al. (2003) A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol 77: 6965-6978.
13. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, et al. (2003) Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 77: 642-658.
14. Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA, (1998) Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 14: 735-740.
15. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, et al. (2004) Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 43: 1410-1417.
16. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, et al. (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 283: 17-25.
17. Zwick MB, Parren PW, Saphire EO, Church S, Wang M, et al. (2003) Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 77: 5863-5876.
18. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
19. Kessler JA 2nd, McKenna PM, Emini EA, Chan CP, Patel MD, et al (1997) Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 13: 575-582.
20. Parren PW, Mondor I, Naniche D, Ditzel HJ, Klasse PJ, et al. (1998) Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 72: 3512-3519.
21. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, et al. (1997) Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 9: 1281-1290.
22. Gorny MK, Mascola JR, Israel ZR, VanCott TC, Williams C, et al. (1998) A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res Hum Retroviruses 14: 213-221.
23. Taniguchi Y, Zolla-Pazner S, Xu Y, Zhang X, Takeda S, et al. (2000) Human monoclonal antibody 98-6 reacts with the fusogenic form of gp41. Virology 273: 333-340.
24. Jeffs SA, Gorny MK, Williams C, Revesz K, Volsky B, et al. (2001) Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol Lett 79: 209-213.
25. Robinson WE Jr, Gorny MK, Xu JY, Mitchell WM, Zolla-Pazner S, (1991) Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 65: 4169-4176.
26. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, et al. (1991) Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 65: 489-493.
27. Thali M, Furman C, Ho DD, Robinson J, Tilley S, et al. (1992) Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 66: 5635-5641.
28. Moore JP, Trkola A, Korber B, Boots LJ, Kessler JA, 2nd, et al (1995) A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol. 69: 122-130.
29. Pietzsch J, Scheid JF, Mouquet H, Klein F, Seaman MS, et al. (2010) Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med 207: 1995-2002.
30. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343.
31. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110.
32. Changela A, Wu X, Yang Y, Zhang B, Zhu J, et al. (2011) Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 85: 2524-2535.
33. Wu X, Yang ZY, Li Y, Hogerkorp CM, (2010) Schief WR, et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
34. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
35. Park EJ, Vujcic LK, Anand R, Theodore TS, Quinnan GV Jr, (1998) Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 72: 7099-7107.
36. Park EJ, Quinnan GV Jr, (1999) Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J Virol 73: 5707-5713.
37. Park EJ, Gorny MK, Zolla-Pazner S, Quinnan GV Jr, (2000) A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol 74: 4183-4191.
38. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
39. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, et al. (2003) Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 100: 15131-15136.
40. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
41. Mascola JR, (2002) Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20: 1922-1925.
42. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, et al. (2001) Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol 8: 350-358.
43. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, et al. (2003) Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. Aids 17: 301-309.
44. Dong M, Zhang PF, Grieder F, Lee J, Krishnamurthy G, et al. (2003) Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol 77: 3119-3130.
45. Quinnan GV Jr, Yu XF, Lewis MG, Zhang PF, Sutter G, et al. (2005) Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol 79: 3358-3369.
46. Vujcic LK, Quinnan GV Jr, (1995) Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 11: 783-787.
47. Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, et al. (2002) A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 76: 644-655.
48. Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, et al. (2007) Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A 104: 10193-10198.
49. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, et al. (2006) Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 80: 1414-1426.
50. Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, et al. (2006) Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology 347: 36-51.
51. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790.
52. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
53. Earl PL, Broder CC, Long D, Lee SA, Peterson J, et al. (1994) Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 68: 3015-3026.
54. Broder CC, Earl PL, Long D, Abedon ST, Moss B, et al. (1994) Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and-sensitive monoclonal antibodies. Proc Natl Acad Sci U S A 91: 11699-11703.
55. Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, et al. (2001) Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 75: 645-653.
56. Earl PL, Broder CC, Doms RW, Moss B, (1997) Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 71: 2674-2684.
57. Broder CC, Nussbaum O, Gutheil WG, Bachovchin WW, Berger EA (1994) CD26 antigen and HIV fusion? Science 264: 1156-1159; author reply 1162-1155.
58. Zhang PF, Chen X, Fu DW, Margolick JB, Quinnan GV Jr, (1999) Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection. J Virol 73: 5225-5230.
59. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S, (1991) Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 65: 4832-4838.
60. Nyambi PN, Nadas A, Mbah HA, Burda S, Williams C, et al. (2000) Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol 74: 10670-10680.
61. Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, et al. (2006) Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology.
62. Quinones-Kochs MI, Buonocore L, Rose JK, (2002) Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 76: 4199-4211.
63. Quan FS, Sailaja G, Skountzou I, Huang C, Vzorov A, et al. (2007) Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 25: 3841-3850.
64. Ma BJ, Alam SM, Go EP, Lu X, Desaire H, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7: e1002200.
65. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, et al. (2006) Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology. 350: 34-47.
66. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, et al. (2009) Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390: 404-409.
67. Moody MA, Yates NL, Amos JD, Drinker MS, Eudailey JA, et al. (2012) HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 86: 7496-7507.